IP Library Granted Patent US 10,450,269
Granted Patent B1
US 10,450,269 · App. 16/446,331 · Granted Oct 22, 2019

Compounds and uses thereof for the modulation of hemoglobin

Inventors: Qing Xu (South San Francisco, CA); Zhe Li (San Diego, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D207/08C07C271/16C07D207/34C07D207/48C07D211/16C07D211/22C07D211/60C07D211/78C07D213/81C07D241/04C07D265/30C07D279/12C07D309/08C07D309/28C07D333/38C07D335/02C07D401/06C07D401/12C07D403/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,269
App. No.
16/446,331
Granted
Oct 22, 2019
Kind
B1
Abstract

Provided herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims (26)

1. A compound of formula:

or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.

2. A compound of formula:

or a pharmaceutically acceptable salt of each thereof.

3. A compound of formula:

4. A compound of formula:

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: XU, QING; LI, ZHE
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 049554/0239 →
Continuity (3)
Continuation 16186275 · Nov 9, 2018
Continuation 14776726
Provisional Application 61905803 · Nov 18, 2013